CNAO REgistry triAL - REGAL: Observational Registry of Patients Treated With Heavy Particle Therapy (Protons and Carbon Ions)

What this Trial Is About

This research aims to collect both past and current data on patients treated with particle therapy, including protons and carbon ions, at the National Center for Oncological Hadrontherapy (CNAO) in Pavia. Particle therapy is a specialized type of radiotherapy that uses charged particles instead of traditional photons to treat cancer, especially tumors that are resistant to radiation or located near sensitive areas. The study seeks to gather detailed information on patient outcomes and treatment effects across multiple types of cancer. Participants receive heavy-ion therapy, also known as hadrontherapy, which involves radiation treatment using protons or carbon ions. The therapy is not assigned by the study but is part of routine clinical care at CNAO. The registry includes multiple patient groups with various tumor types such as brain, ocular, head and neck, thorax, abdomen, pelvic, sarcomas, pediatric tumors, and spine tumors. This ongoing study collects data over a long period to support future research and improve understanding of particle therapy. Patients involved in the study provide informed consent and are monitored through the collection of real-world clinical data. Researchers track disease progression, treatment toxicities, quality of life, and develop predictive models over up to 50 years. The registry helps analyze how cancer evolves and responds to heavy particle therapy, contributing valuable information to guide treatment decisions and support the scientific community. Participants' usual clinical care continues throughout the study.

Longitudinal Registry Including Patients Treated With Heavy Particles